Egrifta (Tesamorelin) Chronic Tendinopathy Protocol

What Is Tesamorelin and Why Is It Being Used for Tendons?

Tesamorelin is an FDA-approved synthetic analogue of endogenous growth-hormone-releasing hormone (GHRH). The FDA cleared it in 2010 specifically to reduce excess abdominal fat in adults with HIV-associated lipodystrophy under the brand name Egrifta SV [1]. Its use in tendinopathy is entirely off-label, meaning no regulatory agency has evaluated it for this purpose.

The rationale for exploring it in tendinopathy is mechanistic. Tesamorelin stimulates the pituitary to release growth hormone (GH), which in turn drives hepatic and local production of insulin-like growth factor-1 (IGF-1). IGF-1 stimulates tenocyte proliferation and type-I collagen synthesis, the two processes most impaired in chronic tendinopathy [2].

The IGF-1 Pathway in Tendon Biology

Tendons in a degenerative state show reduced tenocyte density, disorganized collagen fibrils, and blunted anabolic signaling. A 2010 study in the American Journal of Sports Medicine found that IGF-1 mRNA expression was significantly downregulated in biopsies from patients with chronic Achilles tendinopathy compared with healthy controls [3]. That finding gave the IGF-1 axis a plausible target for intervention.

Growth hormone itself has been shown to accelerate tendon collagen synthesis. In a randomized controlled trial published in the Journal of Clinical Endocrinology and Metabolism (N=12 healthy men), GH administration for 14 days produced a 23% increase in peri-tendinous collagen synthesis rate measured by microdialysis [4]. Tesamorelin, by stimulating endogenous GH rather than supplying exogenous GH directly, may offer a more physiologic and titratable approach.

Why Tesamorelin Rather Than Exogenous GH?

Exogenous recombinant human GH (rhGH) bypasses the normal pulsatile hypothalamic-pituitary axis. Tesamorelin preserves that pulsatility by acting upstream, which means GH release retains some negative-feedback regulation [5]. In the Phase III LIPO trials that supported FDA approval, tesamorelin 2 mg/day raised IGF-1 by a mean of 81 ng/mL from baseline in a non-HIV population subset without causing the supraphysiologic IGF-1 spikes seen with fixed-dose rhGH [6].

Practitioners who use tesamorelin off-label for musculoskeletal repair cite that more controlled IGF-1 rise as a key safety argument. The clinical evidence specifically for tendons, however, remains limited to observational reports and mechanistic extrapolation.

Off-Label Protocol: Dosing and Administration

No published RCT has tested tesamorelin specifically in tendinopathy. The protocol below synthesizes the FDA-approved dosing evidence, mechanistic GH/IGF-1 data, and observational practitioner experience from sports-medicine and regenerative medicine settings. Each element is labeled by evidence level.

Dose

Standard starting dose: 1 mg subcutaneously once daily, administered in the evening to align with the natural nocturnal GH pulse [7].

Dose escalation: If IGF-1 remains below 150 ng/mL at 4 weeks and the patient tolerates the 1 mg dose without glucose dysregulation, some clinicians increase to 2 mg/day. The FDA-approved dose for lipodystrophy is 2 mg/day, providing a safety ceiling grounded in Phase III data [1].

Evidence level: Mechanistic/expert consensus. No tendinopathy-specific dose-finding trial exists.

Route and Injection Technique

Tesamorelin is supplied as a lyophilized powder reconstituted with the provided sterile water diluent. Inject subcutaneously into the abdomen, rotating sites to prevent lipohypertrophy. Do not inject into the same quadrant on consecutive days.

The reconstituted solution should be used within 3 hours or refrigerated and used within 24 hours per Egrifta SV prescribing information [1].

Frequency and Timing

Once-daily dosing, administered 30 to 60 minutes before sleep. GH secretion peaks in the first two hours of slow-wave sleep; dosing near that window may augment the natural nocturnal pulse and improve net IGF-1 exposure [7].

Cycle Length

Minimum meaningful cycle: 12 weeks. Tendon collagen turnover is slow. The half-life of collagen in the Achilles tendon is estimated at roughly 70 days based on carbon-14 dating studies [8]. A 12-week cycle covers approximately two collagen half-lives, which is the minimum period in which structural remodeling could be detectable by ultrasound.

Typical cycle: 16 to 20 weeks for recalcitrant cases where standard physiotherapy and load-management programs lasting more than 3 months have already failed.

After a 20-week cycle, practitioners typically implement an 8-week off period, rechecking IGF-1, fasting glucose, and HbA1c before considering a second cycle.

Evidence level: Observational/mechanistic. Cycle-length recommendations extrapolate from GH tendon-biology data and collagen turnover kinetics, not from a tesamorelin tendinopathy trial.

Monitoring Protocol

Monitoring is non-negotiable given the glucose-dysregulation and IGF-1 supraphysiologic-elevation risks identified in FDA trial data.

Baseline Labs (Before First Injection)

• IGF-1 (ng/mL), age- and sex-referenced
• Fasting glucose and HbA1c
• Comprehensive metabolic panel
• Fasting lipid panel
• PSA (men over 40)
• Pregnancy test (women of reproductive age)
• Pituitary MRI if there is any clinical suspicion of pituitary pathology

Tendon imaging: diagnostic musculoskeletal ultrasound or MRI of the affected tendon to document baseline cross-sectional area, neovascularity, and intratendinous signal changes.

On-Treatment Labs (Every 4 to 6 Weeks)

• IGF-1: target the upper-normal range for patient age and sex (roughly 150 to 300 ng/mL in adults aged 30 to 60). The FDA-approved prescribing information for Egrifta SV instructs clinicians to measure IGF-1 8 weeks after starting treatment and to consider dose reduction if IGF-1 exceeds the upper limit of normal [1].
• Fasting glucose: tesamorelin reduced insulin sensitivity in the LIPO trials; glucose elevations above 125 mg/dL fasting warrant pause and reassessment [6].
• HbA1c: recheck at 12 weeks minimum.

Imaging Reassessment

Musculoskeletal ultrasound at week 12. Compare cross-sectional area and intratendinous echotexture to baseline. A reduction in intratendinous hypoechoic areas or neovascularity suggests favorable remodeling response. Absence of any change by week 16 is a signal to discontinue.

The table below summarizes the monitoring schedule:

| Timepoint | Labs | Imaging | |-----------|------|---------| | Baseline | IGF-1, glucose, HbA1c, CMP, lipids, PSA (men), pregnancy test | Ultrasound or MRI of affected tendon | | Week 4 | IGF-1, fasting glucose | None | | Week 8 | IGF-1, fasting glucose, HbA1c | None | | Week 12 | IGF-1, fasting glucose, HbA1c, CMP | Ultrasound | | Week 16 to 20 (end of cycle) | Full baseline panel | Ultrasound | | 8 weeks post-cycle | IGF-1, fasting glucose, HbA1c | Optional |

Expected Timeline of Clinical Outcomes

Patient expectations should be calibrated carefully. Tesamorelin does not acutely relieve tendon pain. It may support the anabolic environment needed for collagen remodeling, but that process is slow and depends heavily on concurrent rehabilitation loading.

Weeks 1 to 4: No Pain Relief Expected

IGF-1 begins rising within 1 to 2 weeks of initiating tesamorelin, as seen in the FDA approval trial data [6]. Pain scores are not expected to change during this phase. Patients should continue physiotherapy, eccentric loading programs, and any adjunctive modalities prescribed by their physiatrist or sports-medicine physician.

Weeks 4 to 8: Possible Reduction in Morning Stiffness

Some practitioners report that patients notice a modest reduction in morning tendon stiffness by weeks 4 to 8. This is consistent with early improvements in tissue hydration and proteoglycan content rather than structural collagen reorganization. No controlled data exist for this observation in tendinopathy specifically.

Weeks 8 to 16: Structural Remodeling Window

This is the period in which ultrasound changes, if they occur, are most likely to appear. A 2014 study in the British Journal of Sports Medicine found that collagen cross-link maturation in healing tendons required at least 8 to 12 weeks of anabolic stimulation to produce detectable changes in ultrasound tissue characterization [9].

Weeks 16 to 20: Functional Improvement Assessment

By 16 to 20 weeks, patients completing physiotherapy alongside tesamorelin should be assessed with validated outcome tools: the Victorian Institute of Sport Assessment (VISA-A for Achilles, VISA-P for patellar tendon) and the Western Ontario Rotator Cuff (WORC) index for shoulder tendinopathy. A VISA-A score improvement of 20 points or more from baseline is generally considered clinically meaningful [10].

Evidence Base: What the Data Actually Show

This section separates what is known from the GH/IGF-1 literature from what remains extrapolated.

Growth Hormone and Tendon: Controlled Evidence

The strongest direct evidence linking GH to tendon collagen synthesis comes from the Aagaard and Kjaer group in Copenhagen. Their 2001 Journal of Clinical Endocrinology and Metabolism RCT (N=14 elderly men) showed that 3 months of rhGH supplementation increased peri-tendinous collagen synthesis by 36% compared with placebo, measured by 15N-proline incorporation [4]. The Endocrine Society's 2011 Clinical Practice Guideline on GH deficiency notes that GH replacement improves connective tissue mass and may benefit musculoskeletal function in deficient adults [11].

IGF-1 and Tenocyte Biology: Mechanistic Data

A 2015 study in the Journal of Orthopaedic Research (N=8 human tendon cell lines) demonstrated that IGF-1 at concentrations of 100 ng/mL increased tenocyte proliferation by 42% and type-I collagen mRNA expression by 58% versus vehicle control [2]. Those IGF-1 concentrations are achievable with tesamorelin dosing but require careful titration to avoid supraphysiologic levels.

Tesamorelin-Specific Data

The Phase III LIPO-010 trial (N=816), which supported FDA approval of tesamorelin for HIV lipodystrophy, showed a mean IGF-1 increase of 90 ng/mL from baseline at 26 weeks with 2 mg/day dosing [6]. No tendon-specific outcomes were collected in that trial. No published RCT has yet evaluated tesamorelin in any musculoskeletal indication.

The American College of Sports Medicine has not issued a position statement on GH or GHRH peptides for tendon repair as of the date of this article's review.

Evidence level summary for tesamorelin in tendinopathy: Level IV (expert opinion and mechanistic extrapolation). Clinicians and patients must weigh that low evidence level against the burden of recalcitrant tendinopathy and the known tolerability profile from the lipodystrophy RCTs.

Contraindications and Safety

The FDA-approved prescribing information lists the following absolute contraindications for tesamorelin [1]:

• Active malignancy or history of malignancy (IGF-1 may be mitogenic)
• Pregnancy (teratogenicity not ruled out; classified Pregnancy Category X for the lipodystrophy indication)
• Disruption of the hypothalamic-pituitary axis from hypophysitis, tumor, trauma, or surgery
• Hypersensitivity to tesamorelin or mannitol (excipient)

Relative Contraindications

• Pre-existing type 2 diabetes or HbA1c above 6.4%: tesamorelin increased fasting glucose by a mean of 3.1 mg/dL in the LIPO trials, a small but real effect that compounds existing dysglycemia [6].
• Active inflammatory joint disease or systemic infection: GH-mediated immune modulation could theoretically worsen inflammatory states.
• Use of glucocorticoids at pharmacologic doses: glucocorticoids blunt GH secretion and may negate the intended pituitary stimulation [5].

Common Adverse Effects

From FDA trial data: injection-site reactions (6.6%), peripheral edema (6.0%), arthralgia (3.5%), and carpal-tunnel-like paresthesias (3.5%) [1]. Arthralgia is worth flagging in tendinopathy patients because it can be confused with worsening of the underlying condition.

Adjunctive Strategies That Complement Tesamorelin

Tesamorelin is not a substitute for structured rehabilitation. The evidence base for eccentric-loading programs in Achilles and patellar tendinopathy is substantially stronger than for any pharmacologic or peptide intervention.

Eccentric Loading Programs

The Alfredson heavy-load eccentric protocol (3 sets of 15 reps twice daily for 12 weeks) reduced pain scores by a mean of 60% in chronic Achilles tendinopathy in a landmark 1998 American Journal of Sports Medicine trial (N=15) [12]. Any tesamorelin protocol should run concurrently with a supervised eccentric program, not instead of one.

Nutrition: Protein and Collagen Precursors

IGF-1 signaling requires adequate substrate. A 2019 British Journal of Sports Medicine review recommended 0.4 g/kg of gelatin or collagen hydrolysate taken 1 hour before tendon-loading exercise, combined with vitamin C, to optimize collagen synthesis [13]. Patients on tesamorelin who are protein-restricted may see blunted anabolic responses.

Sleep and Recovery

GH is primarily secreted during slow-wave sleep. Sleep deprivation of 24 hours reduces GH pulse amplitude by roughly 60% in controlled studies [7]. Evening tesamorelin dosing loses much of its potential benefit when combined with fragmented sleep patterns.

Patient Selection: Who May Benefit Most

Given the low evidence level and off-label status, the strongest candidate profile for tesamorelin in tendinopathy looks like this:

• Recalcitrant Achilles, patellar, or rotator-cuff tendinopathy confirmed on imaging, present for more than 3 months
• Failure of at least 12 weeks of structured eccentric loading and physiotherapy
• Age-adjusted IGF-1 at or below the mid-normal range at baseline (suggesting sub-optimal anabolic signaling)
• No contraindications listed above
• Willingness to commit to concurrent rehabilitation and monitoring labs every 4 to 6 weeks
• Normal fasting glucose and HbA1c <6.0% at baseline

Patients with IGF-1 already in the upper-normal range may derive less benefit from further IGF-1 elevation and face greater risk of adverse effects.